The Vanguard Group Discloses Position in Mural Oncology

The Vanguard Group, Inc. has filed a Form 8.3, revealing its interests and dealings in the securities of Mural Oncology plc. As stipulated by the Irish Takeover Panel under Rule 8.3, the disclosure documents The Vanguard Group’s position in the company as of 14 August 2025.

The filing shows that The Vanguard Group owns and controls 771,827 ordinary shares of Mural Oncology, representing 4.47% of the company's relevant securities. The disclosure does not include any cash-settled or stock-settled derivatives beyond the owned shares.

Additionally, 64 ordinary shares were sold at a price of 1.77 USD per share. No other dealings, derivative transactions, or option agreements were disclosed. The document affirms there are no indemnities or option arrangements related to their position.